PRME News and Press, First Trust Heitman Global Prime Real Estate ETF From 01/02/26

Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize Canada NewsWire Issued on behalf of Avant Technologies Inc. VANCOUVER, BC , Jan. 2, 2026 /CNW/ -- Equity Insider News Commentary – The gene therapy market is surging toward $36.55 billion by 2032,...

2025-12-31 13:29:53 ET The last time I wrote about Prime Medicine ( PRME ) it was with respect to a Seeking Alpha article entitled as " Prime Medicine: Pressing Forward With Lead Liver Targeting Indications ". With respect to that article, I noted that the company had decided on...

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the publication of Phase 1/2 clinical data with PM359, the Company’s i...

CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Executive Officer of Prime Medicine, will parti...

2025-11-12 14:51:52 ET Prime Medicine, Inc. (PRME) Discusses Liver Disease Franchise Strategy With Focus on Wilson Disease November 12, 2025 8:00 AM EST... Read the full article on Seeking Alpha For further details see: Prime Medicine, Inc. (PRME) Discusses Liver Disease Fra...

CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Executive Officer of Prime Medicine, will parti...

2025-11-07 13:45:30 ET More on Prime Medicine Prime Medicine Momentum Amid Pipeline Progress: Why I Choose To 'Hold' For Now Prime Medicine, Inc. (PRME) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript Prime Medicine, Inc. (PRME) Present...

-- New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial clinical data expected in 2027 -- -- Nominated PM647 as development candidate for Alpha-1 Antitrypsin Deficiency (AATD); on-track to fi...

-- New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial clinical data expected in 2027 -- -- Nominated PM647 as development candidate for Alpha-1 Antitrypsin Deficiency (AATD); on-track to fi...

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer ...